Articles On Botanix Pharmaceuticals (ASX:BOT)

With just five trading days ‘til Christmas, the ASX closed up 0.78% at 8,314 points. Bitcoin jumped to an all-time record high above $US107,000 after Donald Trump confirmed plans for a U.S. strategic reserve for the cryptocurrency. Th...

Immutep, Percheron and PYC feature in clinical trial updates Control Bionics guides to higher revenue, despite ongoing NDIS delays Botanix dispatches its first US prescriptions for its anti-sweat remedy   The year is ending with a bang ra...

Botanix (ASX:BOT) has reported the first prescriptions of its drug Sofdra (sofpironium) to treat hyperhidrosis, a condition of excessive sweating. According to Botanix, the first prescriptions were quickly followed up by the first delive...

Botanix has FDA approval for its treatment for hyperhidrosis, or excessive sweating Sufferers have not had an effective treatment for the socially debilitating disorder Broker E&P Financial Group estimates revenues of close to $100 mil...

True to its history of reinvention and repurposing, Pharmaust will be renamed Neurizon Therapeutics after shareholders approved the moniker change at Wednesday’s AGM. The new name “combines our focus on neuro-degenerative diseases with the...

Alive and Kicking is renowned biotech journo Tim Boreham’s new daily wrap covering morning movers and shakers of note in the ASX Healthcare sector, Monday through Thursday.   Botanix plans a US launch of its anti-sweating treatment in the...

Looking to add a few small-cap ASX healthcare stocks to your portfolio with some outsized growth potential? Considering that the small-cap sector's potential for outsized share price gains comes with added risks, we take a look at two ASX h...

ASX healthcare shares are often touted here on the Australian share market. We are home to some of the most innovative players in the healthcare domain. But there's also a handful of companies that are growing their business over in the...

For biotech investors, the news of an approval by the US FDA is a genuinely exciting milestone. The FDA is the ultimate gatekeeper for the US pharmaceutical market, which is by far the world’s largest. Approval from the FDA not only validat...

The ASX200 reversed its trend to end the week in the green, up 0.35% Nearly all sectors made gains, with Utilities up the most, by 1.9%. Discretionary dipped the most, down 0.4%, Materials and Industrials followed, both falling short, bu...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to end the week with a small gain. At the time of writing, the benchmark index is up 0.1% to 7,777.4 points. Four ASX shares that are rising more than most today are lis...

Botanix Pharmaceuticals Ltd (ASX: BOT) shares are ending the week on a positive note. In morning trade, the clinical dermatology company's shares are up 9% to a 52-week high of 36.5 cents. Why are Botanix Pharmaceuticals shares rising? Inve...

It’s looking like another red day on the market, with the ASX flattish around intraday trades. Sector performance is mixed, with healthcare leading the decline at 0.7%, followed closely by IT which is down half a percent. Today repres...

Botanix Pharmaceuticals (ASX:BOT) on Thursday described itself as having transitioned from a development stage to being revenue-generating dermatology company, following FDA approval for its product Sofdra. Sofdra – sofpironium gel – has...

Control Bionics’s shares surge after TGA approval Control Bionics (ASX:CBL) surged by 51% this morning after announcing a TGA approval for its DROVE autonomous wheelchair module. DROVE has now been officially classified as a Class 1 Medical...

The Botanix Pharmaceuticals Ltd (ASX: BOT) share price will be one to watch closely this week. That's because the clinical dermatology company has just announced some very big news.. Why is the Botanix Pharmaceuticals share price on watch?...

Clinical dermatology company Botanix Pharmaceuticals (ASX:BOT) has announced that the US FDA has approved  Sofdra (sofpironium).

ASX closes lower, but Energy sector blinks green Uranium mining stocks surged on Peter Dutton’s nuclear plans VanEck to launch Australia’s first Bitcoin ETF tomorrow    Local shares closed Wednesday -0.1% lower as gains in Energy were of...

The All Ordinaries Index (ASX: XAO) is up 0.1% in morning trade today, but this ASX All Ords stock isn't going anywhere just yet. Shares in the clinical dermatology company closed at 34 cents apiece yesterday, which sees the stock up a...

FDA panel rejects MDMA for PTSD treatment, citing safety and data concerns Advocates argue MDMA’s benefits outweigh risks, call for further research. South Africa legalises personal cannabis use, setting precedent for African nations    G...

The S&P/ASX 200 Index (ASX: XJO) is having another disappointing session. In afternoon trade, the benchmark index is down 0.65% to 7,705.1 points. Four ASX shares that are not letting that hold them back are listed below. Here's why t...

Clinical dermatology company, Botanix Pharmaceuticals (ASX:BOT) has submitted the last label materials to the US Food & Drug Administration (FDA) for the approval of Sofdra™ a pending prescription treatment for excessive underarm sweati...

ASX biotech shares have been showing significant signs of momentum lately. Exciting clinical trial results and strong investor interest are propelling the sector forward. Plenty of upcoming catalysts and company-specific developments could...

Imricor has two upcoming pivotal trials and is looking to transform cardiac ablation procedures  Botanix Pharmaceuticals is expecting US FDA approval for its lead dermatology product Sofdra in late June Bell Potter is confident in Paradigm...

“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Australian market (ASX) as requested by you! Email us at [email protected] with your stock request. Limit of one per person, no guarantee o...

With a few notable exceptions, ASX cannabis shares widely underperformed again over the last year. That's a far cry from the heady days of 2019 and 2020 when ASX cannabis shares joined their American-listed peers in setting investors' portf...

Where are we in terms of US legalisation of cannabis? What about the current legal landscape for cannabis in Australia? We look at the best performing ASX weed stocks this past month   Global weed stocks have been on bumpy ride over the p...

Momentum investing involves taking advantage of, and making profits from, upward trends in a stock. The strategy takes the position that the stock market’s recent winners will remain winners. Note that there is a big difference between mome...

“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Australian market (ASX) as requested by you! Email us at [email protected] with your stock request. Limit of one per person, no guarantee o...

Botanix Pharmaceuticals (ASX: BOT) Finishes its $13.5 million placement to accelerate its US commercial activities and to increase revenue turnaround The funds raised are for the commercial launch of Sofpironium Bromide gel, and the plac...

Two ASX cannabis shares aren't joining in the broader market rally today. During the Tuesday lunch hour, the All Ordinaries Index (ASX: XAO) is up 0.5%. But cannabis stocks Little Green Pharma Ltd (ASX: LGP) and Botanix Pharmaceuticals Lt...

ASX health sector falls in line with broader markets on macroeconomic factors and global geopolitical tensions Health imaging stock Volpara announces fourth consecutive quarter of operating cashflow Several ASX healthcare names with positi...

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

The ASX200 closed the day down half a per cent. As far as the sector performances, healthcare was the clear leader, picking up a per cent and financials just scraped into positive territory. It was a big day for Strike Energy (STX) a...

Botanix Pharmaceuticals’ (BOT) application to use sofpironium bromide gel to treat primary axillary hyperhidrosis has been knocked back by the US FDA A complete FDA review details key issues centred around the need for instructions to us...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a disappointing decline. The benchmark index is currently down 0.5% to 7,042.6 points. Four ASX shares that are falling more than most today this week are lis...

US FDA requested Botanix to change its instructions paper Antisense says ATL1102 could be effective in muscular dystrophy Actinogen changes Phase 2b design to reduce cost and time to initial results   Botanix plunges after receiving FDA f...

Stockhead’s Top 10 at shortly-before-11-ish, written through a red haze of blazing, sweary anger this morning because the guy who lives across the street has apparently got his leafblower back from having it repaired – after “someone” might...

The Botanix Pharmaceuticals Ltd (ASX: BOT) share price has returned from its trading halt and crashed deep into the red. In morning trade, the cannabis-focused ASX dermatology share is down a massive 36% to 11.5 cents. What's going on with...

ASX health sector falls in line with broader markets as macroeconomic factors continue to create uncertainty Fitch Ratings Agency downgraded the credit rating of Ramsay Health Care (ASX:RHC) to BBB- from BBB Botanix Pharmaceuticals expects...

Cannabis stocks are rebounding, catching short sellers off guard Next signpost for weed investors is the Section 280E of the US IRS tax code We take a look at the best performing weed stocks in last couple of weeks   Having been mauled fo...

The Botanix Pharmaceuticals Ltd (ASX: BOT) share price hit a 52-week high of 21 cents this morning before giving back its gains and dropping into the red. When the ASX cannabis stock hit that level, it meant it was up a massive 160% since...

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

New chief executive has experience executing clinical studies Dr Thurn was formerly part of the TGA’s Drug Safety Evaluation Branch Progress continues to be made on MND and canine cancer trials   PharmAust is strengthening its management...

PharmAust (PAA) appoints Dr Michael Thurn as its newest CEO, effective September 1 The company reports he has extensive experience in drug discovery, regulation and clinical trials Dr Roger Aston will remain as Chair, but transition i...

Botanix Pharmaceuticals (ASX: BOT) has announced that its chief operating officer has been appointed as its chief executive officer.

Botanix Pharmaceuticals (BOT) appoints Dr Howie McKibbon as its newest CEO Dr McKibbon was previously Chief Operating Officer at the company He has more than 25 years of experience in the pharmaceutical industry and has led the launch...

Futures predict the ASX will open lower to finish the week, triggered by tech shares losing momentum on Wall Street and leading the market to also close lower. A highly anticipated speech by the US Federal Reserve chairman on the state o...